Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial | Zendy

Gerd Fätkenheuer | Zendy; Claudine Duvivier | Zendy; Armin Rieger | Zendy; J. Durant | Zendy; D. Rey | Zendy; Warren N. Schmidt | Zendy; A.D. Hill | Zendy; Yvon van Delft | Zendy; Stephan Marks | Zendy; N. Vetter | Zendy; Richard Greil | Zendy; C. Pedersen | Zendy; Merete Storgaard | Zendy; P. Morlat | Zendy; Christine Katlama | Zendy; Laurent Cotte | Zendy; C. Duvvier | Zendy; Christoph Stephan | Zendy; C. Stellbrink | Zendy; Matthias Stoll | Zendy; Albrecht Stoehr | Zendy; Jürgen K. Rockstroh | Zendy; Dénes Bánhegyi | Zendy; L. Itzchak | Zendy; Eduardo Shahar | Zendy; Shlomo Maayan | Zendy; Dan Turner | Zendy; Adriano Lazzarin | Zendy; Andrea Antinori | Zendy; G. Carosi | Zendy; L. Minoli | Zendy; Giovanni Di Perri | Zendy; G. Filice | Zendy; Massimo Andreoni | Zendy; Dan Duiculescu | Zendy; Sorin Rugină | Zendy; Simona Erşcoiu | Zendy; A. Streinu | Zendy; А. В. Пронин | Zendy; Vadim Pokrovsky | Zendy; Б М Груздев | Zendy; Alexey Yakovlev | Zendy; Evgeny Voronin | Zendy; B. Clotet | Zendy; Josep M. Gatell | Zendy; José Ramón Arribas | Zendy; D. Podzamczer | Zendy; Peré Domingo | Zendy; Cristina Álvarez | Zendy; J Quero | Zendy; Hansjakob Furrer | Zendy; J. Feher | Zendy; Sherry Johnson | Zendy; Julie Fox | Zendy; Mark Nelson | Zendy; Michael Fisher | Zendy; Chloe Orkin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

Author(s) -

Gerd Fätkenheuer,

Claudine Duvivier,

Armin Rieger,

J. Durant,

D. Rey,

Warren N. Schmidt,

A.D. Hill,

Yvon van Delft,

Stephan Marks,

N. Vetter,

Richard Greil,

C. Pedersen,

Merete Storgaard,

P. Morlat,

Christine Katlama,

Laurent Cotte,

C. Duvvier,

Christoph Stephan,

C. Stellbrink,

Matthias Stoll,

Albrecht Stoehr,

Jürgen K. Rockstroh,

Dénes Bánhegyi,

L. Itzchak,

Eduardo Shahar,

Shlomo Maayan,

Dan Turner,

Adriano Lazzarin,

Andrea Antinori,

G. Carosi,

L. Minoli,

Giovanni Di Perri,

G. Filice,

Massimo Andreoni,

Dan Duiculescu,

Sorin Rugină,

Simona Erşcoiu,

A. Streinu,

А. В. Пронин,

Vadim Pokrovsky,

Б М Груздев,

Alexey Yakovlev,

Evgeny Voronin,

B. Clotet,

Josep M. Gatell,

José Ramón Arribas,

D. Podzamczer,

Peré Domingo,

Cristina Álvarez,

J Quero,

Hansjakob Furrer,

J. Feher,

Sherry Johnson,

Julie Fox,

Mark Nelson,

Michael Fisher,

Chloe Orkin

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr533

Subject(s) - efavirenz , etravirine , randomized controlled trial , double blind , medicine , pharmacology , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , placebo , pathology , alternative medicine

Etravirine is approved for use in treatment-experienced patients at a dose of 200 mg twice daily. Efavirenz has been associated with greater increases in serum lipids compared with other non-nucleosides in randomized trials of first-line treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research